Showing 4691-4700 of 7028 results for "".
- Sanofi, Coca-Cola Begin Drink Projecthttps://practicaldermatology.com/news/20121018-sanofi_coca-cola_begin_drink_project/2459700/Sanofi and Coca-Cola are collaborating on a line of drinks, called Beautific Oenobiol, that will claim to offer improved skin, stronger hair, and increased vitality. The collaboration will begin with four products made with mineral water, fruit juice, and nutritional ingredients to be sold in French
- Restoration Robotics, Inc. Appoints Cary Rayment to Board of Directorshttps://practicaldermatology.com/news/20121015-restoration_robotics_inc_appoints_cary_rayment_to_board_of_directors/2459706/Cary Rayment joined the Board of Directors of Restoration Robotics, Inc.. He previously served as President and Chief Executive Officer of Alcon, Inc. until 2009 and then as non-executive chairman and director of Alcon, Inc.
- Revance Regains Rights to Its Botulinum Toxinshttps://practicaldermatology.com/news/20121009-revance_regains_rights_to_its_botulinum_toxins/2459713/Revance Therapeutics, Inc. announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A.
- Bovie Medical Promotes Double Warranty, Free Goodshttps://practicaldermatology.com/news/20121002-bovie_medical_promotes_double_warranty_free_goods/2459723/Bovie Medical Corporation started its Fall Festival of Fun promotion now through December 31, 2012. During the promotion, customers receive an increased value of a double warranty and free goods when purchasing the Aaron® 1250, Aaron® 2250, or Aaron® 3250. To find out more information contact a loca
- Aesthetics Course Offers Cosmetic Practitioners Practical Business Advicehttps://practicaldermatology.com/news/20121002-aesthetics_course_offers_cosmetic_practitioners_practical_business_advice/2459724/Registration is now open for “Mastering the Business of Aesthetics” (MBA), a one-day course that teaches vital lessons regarding the financial components of cosmetic practice. The course will take place in Beverly Hills, CA on October 27th and cover topics such as optimizing laser business, increasi
- Valeant Acquires Medicis Pharmaceutical Corp. for $2.6 Billionhttps://practicaldermatology.com/news/20120904-valeant_acquires_medicis_pharmaceutical_for_26_billion/2459743/Valeant Pharmaceuticals announced an agreement to acquire Medicis Pharmaceutical for $44 per share in cash, in a deal worth approximately $2.6 billion. The transaction is expected to close in the first half of 2013 and has been approved by each company's board of directors. The combined operations w
- Neodyne Biosciences Announces Positive Interim Trial Results for Embracehttps://practicaldermatology.com/news/20120807-neodyne_biosciences_announces_positive_interim_trial_results_for_embrace/2459756/Neodyne Biosciences, Inc. announced positive interim results from the REFINE Trial (Scar Prevention and the Clinical Effectiveness of a Novel Mechano-modulating Polymer), a randomized, control clinical trial designed to assess the efficacy and
- Cosmetic Bootcamp Adds Topics to Summer Meetinghttps://practicaldermatology.com/news/20120627-cosmetic_bootcamp_adds_topics_to_summer_meeting/2459778/The Cosmetic Bootcamp, an educational symposium for the core aesthetic specialties, has added topics to its summer sessions. These include Dr. David Sarwer (University of Pennsylvania, a nationally known expert on the psychology of cosmetic pati
- National Eczema Blog Launcheshttps://practicaldermatology.com/news/20120626-national_eczema_blog_launches/2459781/The National Eczema Association recently created a blog featuring guest bloggers on a variety of eczema-related topics. The first post, written by the blogger named “Spanish Key,” provides a patient perspective on eczema research topics and h
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33